Recombinant SARS-CoV-2 vaccine (aimbio)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameRecombinant SARS-CoV-2 vaccine (aimbio)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesAim Vaccine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLiveRNA Therapeutics IncAim Vaccine Co LtdNingbo Rongan Biological Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A